CHO Pharma Inc

CHO Pharma Inc exhibits a strong equity position with a total equity of TWD 24,637,130,000 and a low debt-to-equity ratio of 0.01, indicating a conservative capital structure. The company's liquidity is robust, with a current ratio of 19.47 and cash and equivalents of TWD 40,000,000. However, the company is experiencing significant negative operating and free cash flows, at TWD -279,573,000 and TWD -275,012,000, respectively. Profitability metrics are negative, with a return on equity (ROE) of -11.77% and a return on assets (ROA) of -11.27%. These figures are well below the typical thresholds for pharmaceutical companies, which often aim for ROE and ROA in the positive double-digit range. The company's price-to-book ratio of 4.31 and price-to-tangible-book ratio of 4.31 suggest that the market is valuing the company's intangible assets, such as its drug development pipeline, at a premium. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could pose a concentration risk, particularly if the company's drug development efforts in any one area face regulatory or clinical setbacks. Looking ahead, the company is projected to maintain its current revenue level, with no significant growth expected in the next fiscal year. The negative operating income of TWD -325,841,000 and net income of TWD -290,006,000 indicate that the company is not yet profitable and is likely reinvesting heavily in research and development. Risk factors for CHO Pharma Inc include the high costs and long timelines associated with drug development, the potential for clinical trial failures, and the competitive landscape in the pharmaceutical industry. The company's dilution risk is currently low, with no immediate filing-based flags detected. However, the company's negative cash flows and high R&D expenditures suggest that future dilution could be a concern if additional capital is required. Recent events, as disclosed in the company's filings, include ongoing research and development activities in various drug categories, including monoclonal antibodies and carbohydrate-related vaccines. No significant regulatory or legal issues have been reported in the latest filings.